Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferumoxytol-Enhanced MRI for Lymph Node Imaging in Esophageal Cancer
NCT02857218Phase 1Withdrawn
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Apr 2018
- Primary completion
- Aug 2021
- Modality
- Nanoparticles, Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of ferumoxytol in esophageal cancer, sponsored by OHSU Knight Cancer Institute. Primary endpoints: Practical feasibility up to 18 weeks and Technical feasibility of USPIO-MRI up to 18 weeks. Planned start Apr 2018; status: withdrawn.
02
Drugs
ferumoxytol
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT02857218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02857218.